Natural Product (NP) Details
| General Information of the NP (ID: NP7818) | |||||
|---|---|---|---|---|---|
| Name |
Morroniside
|
||||
| Synonyms |
Morroniside; 25406-64-8; CHEBI:80852; (7Beta-Hydroxy)-Morroniside; methyl (1S,3R,4aS,8S,8aS)-3-hydroxy-1-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,4a,8,8a-hexahydropyrano[3,4-c]pyran-5-carboxylate; CHEMBL1209803; DTXSID60948257; HY-N0532; BDBM50279531; s5465; ZINC56874303; AKOS027250775; CCG-268714; AS-56291; CS-0009065; C17000; Q27151347; (1S)-1alpha-(beta-D-Glucopyranosyloxy)-6alpha-hydroxy-8beta-methyl-4aalpha,5,8,8aalpha-tetrahydro-1H,6H-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester; Methyl 8-(hexopyranosyloxy)-3-hydroxy-1-methyl-4,4a,8,8a-tetrahydro-1H,3H-pyrano[3,4-c]pyran-5-carboxylate
Click to Show/Hide
|
||||
| Species Origin | Cornus officinalis ... | Click to Show/Hide | |||
| Cornus officinalis | |||||
| Disease | Myocardial infarction [ICD-11: BA41] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.814
MDCK Permeability
-5.229
PAMPA
+++
HIA
+
Distribution
VDss
-0.552
PPB
38.7%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
- -
HLM Stability
- - -
Excretion
CLplasma
1.662
T1/2
2.975
Toxicity
DILI
+++
Rat Oral Acute Toxicity
- - -
FDAMDD
- -
Respiratory
- - -
Human Hepatotoxicity
+
Ototoxicity
+++
Drug-induced Nephrotoxicity
+++
Drug-induced Neurotoxicity
- - -
Hematotoxicity
+
Genotoxicity
-
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C17H26O11
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1C2C(CC(O1)O)C(=COC2OC3C(C(C(C(O3)CO)O)O)O)C(=O)OC
|
||||
| InChI |
1S/C17H26O11/c1-6-11-7(3-10(19)26-6)8(15(23)24-2)5-25-16(11)28-17-14(22)13(21)12(20)9(4-18)27-17/h5-7,9-14,16-22H,3-4H2,1-2H3/t6-,7+,9+,10+,11+,12+,13-,14+,16-,17-/m0/s1
|
||||
| InChIKey |
YTZSBJLNMIQROD-SFBCHFHNSA-N
|
||||
| CAS Number |
CAS 25406-64-8
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Diosgenin | Hepatocellular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Experimental
Result(s) |
Combination of morroniside and diosgenin prevents high glucose-induced cardiomyocytes apoptosis. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Molecule Info | [3] | |
| KEGG Pathway | cAMP signaling pathway | Click to Show/Hide | ||
| 2 | Neuroactive ligand-receptor interaction | |||
| 3 | Insulin secretion | |||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | Click to Show/Hide | ||
| 2 | G alpha (s) signalling events | |||
| 3 | Glucagon-type ligand receptors | |||
| WikiPathways | GPCRs, Class B Secretin-like | Click to Show/Hide | ||
| 2 | Integration of energy metabolism | |||
| 3 | GPCR ligand binding | |||
| 4 | GPCR downstream signaling | |||